×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MBRX – moleculin biotech, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MBRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/13
08:51 am
mbrx
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented [Yahoo! Finance]
Low
Report
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented [Yahoo! Finance]
11/13
08:36 am
mbrx
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
Medium
Report
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
11/12
09:01 am
mbrx
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill [Yahoo! Finance]
Low
Report
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill [Yahoo! Finance]
11/12
08:37 am
mbrx
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill
Low
Report
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill
10/30
08:40 am
mbrx
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting
Medium
Report
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting
10/29
08:35 am
mbrx
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
Low
Report
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
10/25
12:09 pm
mbrx
Moleculin Biotech (NASDAQ:MBRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Moleculin Biotech (NASDAQ:MBRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
10/23
08:00 am
mbrx
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
Medium
Report
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:11 pm
mbrx
Form 4 Moleculin Biotech, Inc. For: Nov 12 Filed by: PICKER DONALD H
Low
Report
Form 4 Moleculin Biotech, Inc. For: Nov 12 Filed by: PICKER DONALD H
11/14
04:11 pm
mbrx
Form 4 Moleculin Biotech, Inc. For: Nov 12 Filed by: Foster Jonathan P.
Low
Report
Form 4 Moleculin Biotech, Inc. For: Nov 12 Filed by: Foster Jonathan P.
11/14
04:10 pm
mbrx
Form 4 Moleculin Biotech, Inc. For: Nov 12 Filed by: KLEMP WALTER V
Low
Report
Form 4 Moleculin Biotech, Inc. For: Nov 12 Filed by: KLEMP WALTER V
11/14
04:09 pm
mbrx
Form 4 Moleculin Biotech, Inc. For: Nov 12 Filed by: Yan Joy
Low
Report
Form 4 Moleculin Biotech, Inc. For: Nov 12 Filed by: Yan Joy
11/14
04:09 pm
mbrx
Form 4 Moleculin Biotech, Inc. For: Nov 12 Filed by: Cermak Elizabeth
Low
Report
Form 4 Moleculin Biotech, Inc. For: Nov 12 Filed by: Cermak Elizabeth
11/14
04:08 pm
mbrx
Form 4 Moleculin Biotech, Inc. For: Nov 12 Filed by: Climaco John M
Low
Report
Form 4 Moleculin Biotech, Inc. For: Nov 12 Filed by: Climaco John M
11/14
04:08 pm
mbrx
Form 4 Moleculin Biotech, Inc. For: Nov 12 Filed by: CANNON MICHAEL D
Low
Report
Form 4 Moleculin Biotech, Inc. For: Nov 12 Filed by: CANNON MICHAEL D
11/14
04:07 pm
mbrx
Form 4 Moleculin Biotech, Inc. For: Nov 12 Filed by: George Robert E.
Low
Report
Form 4 Moleculin Biotech, Inc. For: Nov 12 Filed by: George Robert E.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS
41.2%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation 18.0%
3/17 Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus 15.6%
4/13 WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020 [Canadian Business Journal (Canada)] 13.3%
3/23 Form S-3/A Moleculin Biotech, Inc. 9.6%
4/14 Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate 9.4%
10/22 Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications 8.6%
8/16 Q2/2019 6/30/2019 EPS -0.030 ZacksConsensus -0.090 ActVsEst 0.060 - Beat 8.5%
3/4 Form 8-K Moleculin Biotech, Inc. For: Mar 04 7.0%
11/12 Form 8-K Moleculin Biotech, Inc. For: Nov 12 5.9%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation 18.0%
3/17 Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus 15.6%
4/13 WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020 [Canadian Business Journal (Canada)] 13.3%
3/23 Form S-3/A Moleculin Biotech, Inc. 9.6%
4/14 Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate 9.4%
10/22 Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications 8.6%
8/16 Q2/2019 6/30/2019 EPS -0.030 ZacksConsensus -0.090 ActVsEst 0.060 - Beat 8.5%
3/4 Form 8-K Moleculin Biotech, Inc. For: Mar 04 7.0%
11/12 Form 8-K Moleculin Biotech, Inc. For: Nov 12 5.9%
TOP News Decliners
3/19
WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS [Canadian Business Journal (Canada)]
-50.0%
3/17 Form 8-K Moleculin Biotech, Inc. For: Mar 16 -42.2%
3/16 Form 8-K Moleculin Biotech, Inc. For: Mar 13 -25.9%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation [Canadian Business Journal (Canada)] -21.6%
3/20 Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate -20.0%
2/6 Moleculin Biotech Inc (NASDAQ: MBRX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.3%
4/2 Moleculin Announces Additional Positive Safety Data in EU AML Trial -15.0%
8/6 Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models -15.0%
2/3 Form 8-K Moleculin Biotech, Inc. For: Feb 03 -14.8%
2/27 WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia [Canadian Business Journal (Canada)] -13.5%
3/17 Form 8-K Moleculin Biotech, Inc. For: Mar 16 -42.2%
3/16 Form 8-K Moleculin Biotech, Inc. For: Mar 13 -25.9%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation [Canadian Business Journal (Canada)] -21.6%
3/20 Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate -20.0%
2/6 Moleculin Biotech Inc (NASDAQ: MBRX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.3%
4/2 Moleculin Announces Additional Positive Safety Data in EU AML Trial -15.0%
8/6 Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models -15.0%
2/3 Form 8-K Moleculin Biotech, Inc. For: Feb 03 -14.8%
2/27 WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia [Canadian Business Journal (Canada)] -13.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: